Qinlock is owned by Deciphera Pharms.
Qinlock contains Ripretinib.
Qinlock has a total of 10 drug patents out of which 0 drug patents have expired.
Qinlock was authorised for market use on 15 May, 2020.
Qinlock is available in tablet;oral dosage forms.
Qinlock can be used as treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib, treatment of gastrointestinal stromal tumors in patients being treated concurrently with a cyp3a4 inhibitor, treatment of gastrointestinal stromal tumor, treatment of gastrointestinal stromal tumors in patients suffering from palmer-planter erythrodysesthesia syndrome, method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily, treatment of gastrointestinal stromal tumors in patients suffering from hypertension.
Drug patent challenges can be filed against Qinlock from May, 2024.
The generics of Qinlock are possible to be released after 30 December, 2040.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8188113 | DECIPHERA PHARMS | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jul, 2030
(7 years from now) | |
US8461179 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE48731 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Jun, 2032
(9 years from now) | |
US11266635 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US10966966 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11433056 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11344536 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11426390 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11185535 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(17 years from now) | |
US11395818 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 15, 2025 |
Orphan Drug Exclusivity (ODE) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of gastrointestinal stromal tumor; Treatment of gastrointestinal stromal tumors in patients suffering from palmer-planter erythrodysesthesia syndrome; Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib; Method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily; Treatment of gastrointestinal stromal tumors in patients suffering from hypertension; Treatment of gastrointestinal stromal tumors in patients being treated concurrently with a cyp3a4 inhibitor
Dosage: TABLET;ORAL
44
United States
7
China
7
European Union
6
Korea, Republic of
6
Brazil
6
Australia
5
Canada
4
Japan
3
Argentina
3
Israel
3
Taiwan, Province of China
3
EA
2
Mexico
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic